After a two-year review, Health Canada said it will update the product monograph for domperidone, which some women said caused them to have severe panic attacks, anxiety and intrusive thoughts after they stopped taking it.
The U.S. Justice Department has said Sherry-Ann Jenkins was not trained or licensed to provide any medical care but presented herself as a doctor and billed patients for unneeded treatments.
Backed by about $4 million in funding over four years, the GLOW Indigenous Grant is a partnership between pharmaceutical company Gilead Sciences Canada and CAAN Communities, Alliances and Networks.